Pemetrexed Disodium
Injection · trading as Pemetrexed
To Be Discontinued Active (discontinuing) — Day 216
FDA shortage record
- Substance
- Pemetrexed Disodium
- Brand name
- Pemetrexed
- Manufacturer
- Sandoz Inc.
- Dosage form
- Injection
- Presentation
- Pemetrexed Disodium, Injection, 500 mg/20 mL (NDC 0781-3519-90)
- Route(s)
- INTRAVENOUS
- Therapeutic category
- Oncology
- Package NDC
0781-3519-90- Initially posted
- 10/10/2025
- Days on shortage list
- 216
- Discontinued
- 10/10/2025
- Current FDA status
- To Be Discontinued
- Shortage entries (current dataset)
- 2 records for Pemetrexed Disodium
Why this shortage matters
Oncology drugs treat cancers including solid tumors, leukemia, and lymphoma. Shortages of chemotherapy agents can delay or interrupt regimens where dose timing and intensity directly affect treatment outcomes.
FDA therapeutic class: Oncology
Reason and context
Discontinuation of the manufacture of the drug
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 800-525-8747.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3). - FDA UNII identifier:
2PKU919BA9. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.